Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland

• Published in: PLOS ONE
• Main Authors: Hjálmarsdóttir, Martha Ásdís, Haraldsson, Gunnsteinn Ægir, Quirk, Sigríður Júlía, Haraldsson, Ásgeir, Erlendsdóttir, Helga, Kristinsson, Karl Gústaf
• Other Authors: Faculty of Medicine, Clinical Laboratory Services, Diagnostics and Blood Bank, Women's and Childrens's Services, Landspitali - The National University Hospital of Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2020
• Subjects: Sýklalyfjaónæmi; Bóluefni; Biochemistry; Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all); Multidisciplinary; Iceland
• Online Access: https://hdl.handle.net/20.500.11815/3358; https://doi.org/10.1371/journal.pone.0230332

Funding: This work is an investigator-initiated study that was supported by grants from: - The Landspítali University Hospital Research Fund (MÁH) https://www.landspitali.is - GlaxoSmithKline Biologicals SA (KGK, HE, ÁH), https://www.gsk.com The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: This work is an investigator-initiated study that was supported by grants from: - The Landspítali University Hospital Research Fund (MÁH) https://www.landspitali.is - GlaxoSmithKline Biologicals SA https://www.gsk.com The authors declare that this does not alter our adherence to PLOS ONE policies on sharing data and materials. Neither GlaxoSmithKline Biologicals SA, nor Landspítali University Hospital Research Fund had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: Copyright: © 2020 Hjálmarsdóttir et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background Penicillin non-susceptible (PNSP) and multi-resistant pneumococci have been prevalent in Iceland since early nineties, mainly causing problems in treatment of acute otitis media. The 10-valent protein conjugated pneumococcal vaccine (PHiD-CV) was introduced into the childhood vaccination program in 2011. The aim of the study was to investigate the changes in antimicrobial susceptibility and serotype distribution of penicillin non-susceptible pneumococci (PNSP) in Iceland 2011-2017. Methods and findings All pneumococcal isolates identified at the Landspítali University Hospital in 2011-2017, excluding isolates from the nasopharynx and throat were studied. Susceptibility testing was done according to the EUCAST guidelines using disk diffusion with chloramphenicol, erythromycin, clindamycin, tetracycline, ...